We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02429466
Recruitment Status : Completed
First Posted : April 29, 2015
Last Update Posted : September 23, 2020
Information provided by (Responsible Party):
Nasser Hanna, Indiana University School of Medicine

Brief Summary:
This is an open-label, single arm, Phase I dose escalation study in subjects with refractory germ cell tumor (rGCT). This phase I will evaluate the safety and efficacy of SGI-110 in combination with cisplatin in subjects with rGCT. The primary objective is to determine the maximum tolerated dose (MTD) of SGI-110 to be used prior to cisplatin. A total of 15 subjects will be enrolled in this study at the Indiana University Simon Cancer Center.

Condition or disease Intervention/treatment Phase
Germ Cell Tumor Testis Cancer Testicular Cancer Drug: Guadecitabine (SGI-110) Phase 1

Detailed Description:

Primary Objective:

To assess the safety and toxicity of guadecitabine (SGI-110) plus cisplatin including the dose limiting toxicity (DLT) and to determine the Maximum tolerated dose (MTD)

Secondary Objective:

To assess the efficacy of guadecitabine (SGI-110) to resume sensitivity to cisplatin in refractory GCT

Correlative Objective:

To evaluate the pharmacodynamic activity of guadecitabine (SGI-110) Evaluate miRNA biomarkers in serum on day 1 of cycles 1-6

Intervention and Mode of Delivery: Guadecitabine (SGI-110) will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.

Duration of Intervention and Evaluation:

Treatment will be continued for a maximum of 6 cycles or until disease progression or unacceptable toxicity whichever occurs first. Subjects who are responding to therapy without major toxicty would be allowed to continue on single agent guadecitabine (SGI-110) at the MTD after 4-6 cycles of the combination therapy until disease progression. Subjects will be followed after the last cycle every 2 months for the 1st year, and every 4 months thereafter until death (expected overall survival less than 12 months).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Actual Study Start Date : April 27, 2015
Actual Primary Completion Date : June 4, 2018
Actual Study Completion Date : February 13, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Cisplatin

Arm Intervention/treatment
Experimental: Guadecitabine (SGI-110) Drug: Guadecitabine (SGI-110)
SGI-110 will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.
Other Name: Guadecitabine

Primary Outcome Measures :
  1. Dose limiting toxicity (DLT) of guadecitabine (SGI-110) plus cisplatin [ Time Frame: During chemotherapy (weeks 1-18) ]
  2. Maximum tolerated dose (MTD) of SGI-110 plus cisplatin [ Time Frame: During chemotherapy (weeks 1-18) ]

Secondary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Days 42, 84, 126, 159, and 220 ]
    To evaluate Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST)

  2. Progression free survival (PFS) [ Time Frame: Days 42, 84, 126, 159, and 220 ]
    The investigators will look at the duration between starting the therapy until progression of disease of subjects on this study

Other Outcome Measures:
  1. Pharmacodynamic activity of SGI-110 [ Time Frame: Day 8 ]
    Blood collection to measure change in peripheral blood mononuclear cells (PBMCs), global DNA and selected genes, and expression of DNMT levels

  2. Pharmacodynamic activity of SGI-110 [ Time Frame: Day 8 ]
    Tumor tissue collection to measure change in global DNA and selected tumor genes, and expression of DNMT levels

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. ≥ 18 years old at the time of informed consent
  2. Written informed consent and HIPAA authorization for release of personal health information.
  3. Subjects who are willing and able to comply with the protocol and study procedures including willingness to undergo tumor biopsy for tumor cells before therapy at Cycle 1, Day 1, and Day 8 (before cisplatin dose) if this is clinically and safely feasible to do so.
  4. Subjects with histologically or serologically confirmed diagnosis of recurrent germ cell tumor.
  5. Subjects who have platinum-resistant disease. There is no limit on the number of prior treatment regimens.
  6. Subjects must have had prior high dose chemotherapy (HDCT) treatment when indicated.
  7. Subjects who have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or elevated Tumor markers (hCG or AFP).

    Note: patients without measurable disease are allowed on the study as long as they have clearly rising tumor markers and they will be exempt from biopsy.

  8. Subjects with ECOG performance status of 0-2.
  9. Subjects must be at least 3 weeks from last chemotherapy.
  10. Females of childbearing potential must not be pregnant or breast-feeding. Male and female patients of reproductive potential must agree to use two forms of highly effective contraception from the screening visit through 30 days after the last dose of study drug. Acceptable forms of effective contraception include:

    • Oral, injected or implanted hormonal methods of contraception.
    • Placement of an intrauterine device (IUD) or intrauterine system (IUS).
    • Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
    • Male sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate).
    • True abstinence: When this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.] Pregnancy tests for females of childbearing potential are required; must be serum at screening and the post treatment safety assessment visit. A positive urine pregnancy test must be confirmed by a serum pregnancy test and a pelvic US since some NSGCT may secrete beta-hCG and cause a false positive pregnancy. A pelvic US does not need to be repeated with each cycle unless the treating physician thinks it is necessary to do so.
  11. The following laboratory values must be obtained within 14 days prior to registration for protocol therapy.

    • Absolute neutrophil count ≥ 1500 cells/mm3
    • Hemoglobin (Hgb) ≥ 8 g/dL
    • Platelets count ≥ 100,000 cells/mm3
    • Serum creatinine levels ≤ 1.5 mg/dl and calculated (by Cockcroft-Gault formula) or measured creatinine clearance ≥ 50 mL/min
    • Bilirubin ≤ 2 x ULN
    • Aspartate aminotransferase (AST, SGOT) ≤ 3 x ULN
    • Alanine aminotransferase (ALT, SGPT) ≤ 3 x ULN

Exclusion Criteria:

  1. Active central nervous system (CNS) metastases. Subjects with neurological symptoms should undergo a head CT scan or brain MRI to exclude brain metastasis, at the discretion of the treating physician.

    NOTE: A subject with prior brain metastasis may be considered if they have completed their treatment for brain metastasis, no longer require corticosteroids, and are asymptomatic.

  2. Treatment with any investigational agent within 30 days prior to registration for protocol therapy.
  3. Concurrent participation in a clinical trial which involves another investigational agent.
  4. Subjects with Grade 2 or greater neuropathy.
  5. Subjects with a life-threatening illness, medical condition or organ system dysfunction, or other reasons which, in the Investigator's opinion, could compromise the subject's safety, interfere with or compromise the integrity of the study outcomes including incomplete recovery from the acute effects from any prior anti-neoplastic therapy.
  6. Pregnancy or breast-feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02429466

Layout table for location information
United States, Indiana
Indiana University Hospital
Indianapolis, Indiana, United States, 46202
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Nasser Hanna
Layout table for investigator information
Principal Investigator: Nasser Hanna, MD Indiana University School of Medicine
Layout table for additonal information
Responsible Party: Nasser Hanna, Assistant Professor of Clinical Medicine, Indiana University School of Medicine
ClinicalTrials.gov Identifier: NCT02429466    
Other Study ID Numbers: IUCRO-0508
1502729080 ( Other Identifier: Indiana University IRB )
First Posted: April 29, 2015    Key Record Dates
Last Update Posted: September 23, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Nasser Hanna, Indiana University School of Medicine:
testicular germ cell tumor
ovarian germ cell tumor
platinum refractory
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Germ Cell and Embryonal
Testicular Neoplasms
Neoplasms by Histologic Type
Endocrine Gland Neoplasms
Neoplasms by Site
Genital Neoplasms, Male
Urogenital Neoplasms
Endocrine System Diseases
Testicular Diseases
Gonadal Disorders
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors